-
Head and neck squamous cell carcinoma (LA-HNSCC and Metastatic HNSCC)–Tumour Deck
Price range: $11,800.00 through $20,000.00Select options This product has multiple variants. The options may be chosen on the product pageThe research study conducted by Mellalta Meets provides insights into the Head and neck squamous cell carcinoma covering both LA-HNSCC and Metastatic HNSCC market dynamics, treatment trends, and key opportunities in the G7 regions. It highlights the need for novel targeted therapies, the potential of biomarker strategies, and the significant market opportunity for drug developers targeting the HNSCC population. The study serves as a comprehensive resource for understanding the current landscape and future prospects of HNSCC treatment.
-
HER2-Low Metastatic Breast Cancer –Tumour Deck
Price range: $11,800.00 through $20,000.00Select options This product has multiple variants. The options may be chosen on the product pageThe research study conducted by Mellalta Meets provides insights into the HER2-Low Metastatic Breast Cancer market dynamics, treatment trends, and key opportunities in the G7 regions. It highlights the need for novel targeted therapies, the potential of biomarker strategies, and the significant market opportunity for drug developers targeting the HER2-Low population. The study serves as a comprehensive resource for understanding the current landscape and future prospects of HER2-Low mBC treatment.
-
Acute Myeloid Leukemia (AML) -The Changing Landscape of Treatment in AML, Executive Deck 2022
Price range: $5,000.00 through $25,000.00Select options This product has multiple variants. The options may be chosen on the product pageAcute myelogenous leukemia (AML) Disease Landscape provides comprehensive market intelligence with epidemiology, keen insight into current treatment paradigms, in-depth pipeline coverage ( ~ 500 unique industry-sponsored studies) and clinical trial landscape supported by detailed recent results from ASH 2022, ASCO 2022 and EHA 2022. The drugs are further classified according to the class of therapies: antibody drug conjugates, bispecific antibodies, tri-specific and monoclonal antibodies, CAR-T therapies & T cells therapies, vaccines, small molecules and others.
Call us today: +1 (304) 470-2225
English
You can use WPML or Polylang and their language switchers in this area.